Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage biopharma announced Monday. In a study that tested the highest dosage of 100-mg, the drug — known as KV2735 — resulted in an average of 6.8% body weight reduction after 28 days compared to placebo.
20hon MSN
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback